Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-03-31 Governance Information
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
TERMS OF REFERENCE OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE OF THE BOARD
Governance Information Classification · 100% confidence The document is titled 'TERMS OF REFERENCE OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE OF THE BOARD' and details the constitution, membership, authorities, duties, decision-making procedures, and other governance aspects of the ESG Committee of the Board. It is a governance-related document focusing on the internal rules and responsibilities of a board committee related to ESG matters. There are no financial statements, audit results, or regulatory filings. It is not a report publication announcement or a certification. The content fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including committee terms of reference.
2021-03-31 English
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of RemeGen Co., Ltd. regarding a change in the company's principal place of business in Hong Kong. It is a brief notice without any financial data, regulatory certifications, or detailed report content. It does not relate to financial results, management changes, or shareholder votes but is a corporate announcement about office location. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-26 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020' and contains detailed consolidated financial results, business highlights, management discussion and analysis, product pipeline, and clinical trial updates for the full fiscal year 2020. It includes financial figures such as bank balances, expenses, losses, and adjusted net loss, as well as extensive narrative on business operations and clinical progress. The length is substantial (15,000 characters), and the content is comprehensive, indicating it is the full annual report rather than a brief announcement or a certification. The document is not a mere announcement of report publication, nor is it a certification or a regulatory filing. It is not a quarterly or interim report, but a full year report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-03-26 English
SUPPLEMENTAL ANNOUNCEMENT TO THE PROFIT WARNING
Regulatory Filings Classification · 95% confidence The document is a supplemental announcement to a profit warning made by Overseas Chinese Town (Asia) Holdings Limited. It references a previous announcement dated 22 March 2021 and provides an update on the expected significant decrease in profit for the year ended 31 December 2020 based on unaudited management accounts. The document explicitly states that the full financial results are still being prepared and will be disclosed in the forthcoming annual results announcement expected at the end of March 2021. The document is relatively short (3237 characters) and serves as an update or announcement rather than a full financial report. It does not contain detailed financial statements or substantive financial data but rather preliminary information and cautionary advice to shareholders and investors. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement providing an update on financial expectations without being the full report itself.
2021-03-25 English
INSIDE INFORMATION ANNOUNCEMENT - APPROVAL BY THE CSRC OF THE APPLICATION IN RESPECT OF H SHARE FULL CIRCULATION PROGRAMME OF THE COMPANY
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the approval by the China Securities Regulatory Commission (CSRC) of the company's application for an H share full circulation programme. It discusses the conversion of unlisted shares into H shares and their listing on the Stock Exchange. The document is relatively short (2874 characters) and serves as an official announcement of regulatory approval and future plans, rather than a detailed financial report or data. It does not contain financial statements or detailed analysis, nor is it a report itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-03-25 English
POLL RESULTS OF THE 2021 FIRST EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the 2021 first extraordinary general meeting (EGM) of RemeGen Co., Ltd. It details the voting outcomes on special resolutions, including the number of votes for, against, and abstentions. The text references the meeting date, location, and shareholder attendance but does not contain financial statements or detailed financial analysis. The document is relatively short (4075 characters) and serves to officially communicate the voting results rather than the meeting materials or full reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-03-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.